The role of fibric acids in atherosclerosis.

被引:148
作者
Fruchart J.C. [1 ]
Staels B. [1 ]
Duriez P. [1 ]
机构
[1] Inserm U325, Départment d' Athérosclérose, Institut Pasteur et Université de Lille, Lille
关键词
Fenofibrate; Bezafibrate; Fenofibric Acid; Minimum Lumen Diameter; Ciprofibrate;
D O I
10.1007/s11883-001-0015-x
中图分类号
学科分类号
摘要
The hypolipidemic fibric acid drugs are peroxisome proliferator-activated receptor a (PPAR alpha) ligands. PPAR alpha activated by fibric acids form heterodimers with the 9-cis retinoic acid receptor (RXR). The PPAR/RXR heterodimers bind to peroxisome proliferator response elements (PPRE), which are located in numerous gene promoters and increase the level of the expression of mRNAs encoded by PPAR alpha target genes. Fibric acids decrease triglyceride plasma levels through increases in the expression of genes involved in fatty acid-beta oxidation. Furthermore, they decrease triglycerides by increasing lipoprotein lipase gene expression and by decreasing apolipoprotein C-III gene expression. Fibric acids increase high-density lipoprotein (HDL) cholesterol partly by increasing apolipoprotein A-I and apolipoprotein A-II gene expression. Fibric acids also reduce vascular wall inflammation and the expression of genes involved in different vascular functions (ie, vasomotricity, thrombosis). Fibric acids are used to treat primary hypertriglyceridemia and mixed hyperlipidemia. Some fibric acid molecules are active in essential hypercholesterolemia. Clinical evidence shows that fibric acids reduce coronary atherosclerosis progression in dyslipidemic patients (eg, bezafibrate, gemfibrozil) and in type 2 diabetic patients (fenofibrate). Gemfibrozil decreases coronary morbidity and mortality in patients with low HDL cholesterol, normal triglycerides,and normal low-density lipoprotein (LDL) cholesterol plasma levels. Further clinical studies are necessary to investigate if fibric acids decrease cardiovascular mortality in type 2 diabetes and in primary prevention of hypertriglyceridemia and hypolipidemia.
引用
收藏
页码:83 / 92
页数:9
相关论文
共 201 条
  • [1] Braissant O(1996)Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and -gamma in the adult rat Endocrinology 137 354-366
  • [2] Foufelle F(1997)Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay Mol Endocrinol 11 779-791
  • [3] Scotto C(1990)Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 645-650
  • [4] Krey G(1999)Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter Toxicol Lett 110 119-127
  • [5] Braissant O(2000)The PPARs: from orphan receptors to drug discovery J Med Chem 43 527-550
  • [6] L’Horset F(1995)Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor J Clin Invest 96 741-750
  • [7] Issemann I(1990)Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study Clin Ther 12 482-488
  • [8] Green S(1991)Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil J Intern Med 229 427-434
  • [9] Lambe KG(1996)The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation Biochim Biophys Acta 1302 93-109
  • [10] Woodyatt NJ(1997)Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPAR-gamma activators J Biol Chem 272 28210-28217